Immunome Presents Additional Phase 3 Varegacestat Data in Desmoid Tumors
At ESMO 2026, Immunome presented additional RINGSIDE data showing improved symptom and physical function scores versus placebo. The FDA accepted the NDA, with a PDUFA date of April 28, 2027.